35 results about "Activation lymphocyte" patented technology

Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28 / B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. Further disclosed are specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed.Also disclosed is the use of the CD28 molecule or any fragment thereof comprising the sAg binding site in a method of screening for a test substance which specifically binds to the CD28 molecule and is capable of antagonizing pyrogenic exotoxin-mediated activation of Th1 lymphocytes.

Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway by a pyrogenic exotoxin. The direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member is inhibited using immunomodulatory peptides. Specific antagonist immunomodulatory peptides comprise amino acid sequences derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed. Such molecules may be used in screening for a test substance which specifically binds to the CD28 molecule and is capable of antagonizing pyrogenic exotoxin-mediated activation of Th1 lymphocytes.

Methods for determining MHC class II binding activity of a preparation comprising lymphocyte activation gene-3 (LAG-3) protein, or a fragment, derivative, or analogue thereof, is described. The methods comprise determining binding of the LAG-3 protein, fragment, derivative, or analogue to MHC class II molecules using bio-layer interferometry (BLI). Such methods can be used as a quality control assay in good manufacturing practice (GMP) grade production of such compounds. Probes and kits for carrying out the methods are also described.

The invention provides a thiophene[3,2-d]pyrimidine compound as shown in a structural formula I as well as a preparation method and application thereof. The compound or pharmaceutically acceptable salt has remarkable inhibition effect on Bruton tyrosine kinase (BTK), has high BTK inhibition activity and high kinase selectivity, and has strong immunosuppressive activity effect. The compound or pharmaceutically acceptable salt has low cytotoxicity on mouse primary lymphocytes, has remarkable inhibition activity on lipopolysaccharide (LPS)-induced B lymphocyte activation and proliferation, has alarge administration window and high safety, and can be widely applied in the field of treatment of inflammation, immune system diseases and malignant tumor. (The formula is as shown in the description).

The present invention can provide a culture container capable of activating lymphocytes more efficiently than conventional ones, and a method for producing the same. The present invention is a bag-shaped culture container made of flexible packaging material for activating lymphocytes, and the inner surface of the opposite container is treated with 10-300ng / cm 2 The density is immobilized with anti-CD3 antibody, and the density per 1cm 2 The anti-CD3 antibody in the form of a solution is sealed in an amount of 0.25 to 400 ng and 0.1 to 800 μl on the culture surface composed of the above-mentioned one surface. In addition, in a bag-shaped culture container made of a flexible packaging material, the anti-CD3 antibody was immobilized at the above-mentioned density on the inner surface of the container facing each other, and the anti-CD3 antibody in solution was sealed in the above-mentioned amount.

The invention provides a kit for detecting human regulatory T cell subtypes and a detection method thereof, belonging to the technical field of cell subtype detection. The kit provided by the invention includes the following components: blood dilution solution, mononuclear cell separation solution, cell culture solution, lymphocyte activation solution, dead cell removal dye, FcR blocking agent, fluorescently labeled anti-human cell surface marker molecule Antibodies, fluorescently labeled antibodies against human intracellular molecules, PBS buffer, lipopolysaccharide, washing buffer, cell staining buffer, cell fixative, and permembrane wash. During the detection, the mononuclear cells in the whole blood are first isolated, and then the human peripheral blood mononuclear cells are stimulated, and finally the regulatory T cell subtypes can be detected by fluorescent antibody staining. By using the kit and detection method of the present invention, 2-6 subtypes of regulatory T cells can be easily and quickly distinguished.

Nucleic acid aptamers capable of binding to lymphocyte activation gene 3 (LAG-3) and uses thereof for modulating immune responses. Such aptamers may comprise a G-rich motif, for example, GX1GGGX2GGTX3A (SEQ ID No: 1), in which each of X1 and X2 are independently G, C, or absent, and X3 is T or C, or L- (G)n-L', in which n is an integer of 5-9 inclusive, and L and L'are nucleotide segments having complementary sequences. Also provided herein are multimeric nucleic acid aptamers containing a backbone moiety, which comprises a palindromic sequence.

The invention relates to a CD5L-binding agent or a pharmaceutical composition thereof for use in the treatment of cancer by inhibiting macrophage M2 activation or promoting lymphocyte activation.